Phaseline

Companies › Lomond Therapeutics Holdings

Lomond Therapeutics Holdings: clinical trials, targets and expected readouts

2 active drug programs in 3 registered trials: 3 Phase 1; Other, Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Lonitoclax (ZE50-0134)
BCL2 inhibitor
BCL2Phase 1Acute Myeloid Leukemia; CLL / SLLDec 2026
ZE46-0134
FLT3 inhibitor; spliceosome modulator
–Phase 1AML With Gene MutationsDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07303660Lonitoclax (ZE50-0134)Phase 1Acute Myeloid LeukemiaOncologyDec 2026
NCT06366789ZE46-0134Phase 1AML With Gene MutationsOtherDec 2027
NCT06708897Lonitoclax (ZE50-0134)Phase 1CLL / SLLOncologyJan 2028

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

BCL2 (1)

Companies with the same targets

Ascentage Pharma Group AbbVie BeOne Medicines Bio-Path Holdings BeiGene Shanghai Fosun Pharmaceutical Industrial Development Guangzhou Lupeng Pharmaceutical Company Cothera Bioscience

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.